Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
TNBC is noted for its aggressive behavior and poor prognosis. Recently developed HER2 target agents have shown potential benefit even in HER2-low expressing breast cancers. This study retrospectively analyzed 2542 non-metastatic TNBC patients from 2008 to 2020, revealing that 26.0% were HER2-low. Data on demographics, tumor characteristics, pathologic complete response (pCR) rates and disease-free survival (DFS), distant metastasis-free survival (DMFS), overall survival (OS), and breast cancer-specific survival (BCSS) were analyzed. The HER2-low group, compared to the HER2-0 group, showed significantly better DFS, DMFS, OS, BCSS ( = 0.0072, = 0.0096, = 0.0180, and = 0.0001, respectively) with older age and higher rates of postmenopausal status ( < 0.0001). No significant differences in pCR rates were observed. Multivariate analyses identified HER2 status as a significant prognostic factor for DFS ( = 0.048), DMFS ( = 0.018), OS ( = 0.049), and BCSS ( = 0.008). Subgroup analysis revealed that these effects varied with menopausal status, showing more pronounced benefits in postmenopausal women. Our findings suggest that HER2-low TNBC patients exhibit a distinct clinical profile and improved survival compared to HER2-0 TNBC patients, especially in postmenopausal patients. Further research on estrogen and HER2 interaction is needed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11274797 | PMC |
| http://dx.doi.org/10.3390/cancers16142566 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unravelling novel microbial players in the breast tissue of TNBC patients: a meta-analytic perspective.
NPJ Biofilms Microbiomes
September 2025
Bioinformatics Group, Centre for Informatics Science (CIS), School of Information Technology and Computer Science (ITCS), Nile University, Giza, Egypt.
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer (BC), accounting for nearly 40% of BC-related deaths. Emerging evidence suggests that the breast tissue microbiome harbors distinct microbial communities; however, the microbiome specific to TNBC remains largely unexplored. This study presents the first comprehensive meta-analysis of the TNBC tissue microbiome, consolidating 16S rRNA amplicon sequencing data from 200 BC samples across four independent cohorts.
View Article and Find Full Text PDFThe USP8/CEP55/CHMP6 Axis Orchestrates Triple-Negative Breast Cancer Progression by Regulating Ferroptosis and Macrophage M2 Polarization.
Clin Breast Cancer
August 2025
Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Electronic address:
Background: Triple-negative breast cancer (TNBC) carries a substantial risk of recurrence and metastasis, posing significant threats to patients' health and quality of life. Centrosomal protein 55 (CEP55) has been demonstrated to exhibit elevated expression levels in TNBC. However, its molecular regulatory mechanism in TNBC remains unclear.
View Article and Find Full Text PDFSparking malignancy: nicotine as a driver of stemness and metastasis in triple-negative breast cancer.
J Pathol
September 2025
Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Triple-negative breast cancer (TNBC) lacks expression of estrogen receptor (ER), progesterone receptor (PR), and HER2, and remains one of the most aggressive and therapeutically challenging breast cancer subtypes, marked by early relapse, metastasis, and limited targeted treatment options. In a recent study published in The Journal of Pathology, Kuo et al provide compelling evidence that nicotine exposure, whether from tobacco smoke or e-cigarette vapor, drives TNBC progression by promoting stem-like and metastatic phenotypes. Integrating clinical datasets, patient tissues, cell lines, and in vivo models, the authors demonstrate that nicotine enhances tumor aggressiveness via coordinated upregulation of CHRNA9 and IGF1R.
View Article and Find Full Text PDFPrognostic Utility of a Deep Learning Radiomics Nomogram Integrating Ultrasound and Multi-Sequence MRI in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.
J Ultrasound Med
September 2025
Department of Ultrasound, Donghai Hospital Affiliated to Kangda College of Nanjing Medical University, Lianyungang, China.
Objective: The aim of this study is to evaluate the prognostic performance of a nomogram integrating clinical parameters with deep learning radiomics (DLRN) features derived from ultrasound and multi-sequence magnetic resonance imaging (MRI) for predicting survival, recurrence, and metastasis in patients diagnosed with triple-negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy (NAC).
Methods: This retrospective, multicenter study included 103 patients with histopathologically confirmed TNBC across four institutions. The training group comprised 72 cases from the First People's Hospital of Lianyungang, while the validation group included 31 cases from three external centers.
Triple-Negative Breast Cancer Presenting as Recurrent Cystic Lesions During Lactation: A Case Report.
Clin Case Rep
September 2025
Department of Thoracic Surgery, Fu Xing Hospital, the Eighth Clinical Medical College Capital Medical University Beijing China.
Lactation-associated breast cancer poses diagnostic challenges due to physiological breast changes that may mask malignancies. Triple-negative breast cancer (TNBC) during lactation is rare and aggressive, requiring vigilant evaluation and treatment. This report highlights the diagnostic dilemma of recurrent cystic breast lesions during lactation, which can mimic benign conditions like galactoceles but may conceal aggressive TNBC, leading to potential delays in diagnosis despite initial conservative approaches such as aspiration.
View Article and Find Full Text PDF